Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1 H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors.

Kettle JG, Anjum R, Barry E, Bhavsar D, Brown C, Boyd S, Campbell A, Goldberg K, Grondine M, Guichard S, Hardy CJ, Hunt T, Jones RDO, Li X, Moleva O, Ogg D, Overman RC, Packer MJ, Pearson S, Schimpl M, Shao W, Smith A, Smith JM, Stead D, Stokes S, Tucker M, Ye Y.

J Med Chem. 2018 Oct 11;61(19):8797-8810. doi: 10.1021/acs.jmedchem.8b00938. Epub 2018 Sep 24.

PMID:
30204441
2.

Potent and selective bivalent inhibitors of BET bromodomains.

Waring MJ, Chen H, Rabow AA, Walker G, Bobby R, Boiko S, Bradbury RH, Callis R, Clark E, Dale I, Daniels DL, Dulak A, Flavell L, Holdgate G, Jowitt TA, Kikhney A, McAlister M, Méndez J, Ogg D, Patel J, Petteruti P, Robb GR, Robers MB, Saif S, Stratton N, Svergun DI, Wang W, Whittaker D, Wilson DM, Yao Y.

Nat Chem Biol. 2016 Dec;12(12):1097-1104. doi: 10.1038/nchembio.2210. Epub 2016 Oct 24.

PMID:
27775716
3.

Discovery of a novel allosteric inhibitor-binding site in ERK5: comparison with the canonical kinase hinge ATP-binding site.

Chen H, Tucker J, Wang X, Gavine PR, Phillips C, Augustin MA, Schreiner P, Steinbacher S, Preston M, Ogg D.

Acta Crystallogr D Struct Biol. 2016 May;72(Pt 5):682-93. doi: 10.1107/S2059798316004502. Epub 2016 Apr 26.

4.

Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.

Patani H, Bunney TD, Thiyagarajan N, Norman RA, Ogg D, Breed J, Ashford P, Potterton A, Edwards M, Williams SV, Thomson GS, Pang CS, Knowles MA, Breeze AL, Orengo C, Phillips C, Katan M.

Oncotarget. 2016 Apr 26;7(17):24252-68. doi: 10.18632/oncotarget.8132.

5.

Predicting the relative binding affinity of mineralocorticoid receptor antagonists by density functional methods.

Roos K, Hogner A, Ogg D, Packer MJ, Hansson E, Granberg KL, Evertsson E, Nordqvist A.

J Comput Aided Mol Des. 2015 Dec;29(12):1109-22. doi: 10.1007/s10822-015-9880-1. Epub 2015 Nov 16.

PMID:
26572910
6.

Pyrimidinone nicotinamide mimetics as selective tankyrase and wnt pathway inhibitors suitable for in vivo pharmacology.

Johannes JW, Almeida L, Barlaam B, Boriack-Sjodin PA, Casella R, Croft RA, Dishington AP, Gingipalli L, Gu C, Hawkins JL, Holmes JL, Howard T, Huang J, Ioannidis S, Kazmirski S, Lamb ML, McGuire TM, Moore JE, Ogg D, Patel A, Pike KG, Pontz T, Robb GR, Su N, Wang H, Wu X, Zhang HJ, Zhang Y, Zheng X, Wang T.

ACS Med Chem Lett. 2015 Jan 13;6(3):254-9. doi: 10.1021/ml5003663. eCollection 2015 Mar 12.

7.

Thiazolopyridone ureas as DNA gyrase B inhibitors: optimization of antitubercular activity and efficacy.

Kale RR, Kale MG, Waterson D, Raichurkar A, Hameed SP, Manjunatha MR, Kishore Reddy BK, Malolanarasimhan K, Shinde V, Koushik K, Jena LK, Menasinakai S, Humnabadkar V, Madhavapeddi P, Basavarajappa H, Sharma S, Nandishaiah R, Mahesh Kumar KN, Ganguly S, Ahuja V, Gaonkar S, Naveen Kumar CN, Ogg D, Boriack-Sjodin PA, Sambandamurthy VK, de Sousa SM, Ghorpade SR.

Bioorg Med Chem Lett. 2014 Feb 1;24(3):870-9. doi: 10.1016/j.bmcl.2013.12.080. Epub 2013 Dec 25.

PMID:
24405701
8.

Thiazolopyridine ureas as novel antitubercular agents acting through inhibition of DNA Gyrase B.

Kale MG, Raichurkar A, P SH, Waterson D, McKinney D, Manjunatha MR, Kranthi U, Koushik K, Jena Lk, Shinde V, Rudrapatna S, Barde S, Humnabadkar V, Madhavapeddi P, Basavarajappa H, Ghosh A, Ramya VK, Guptha S, Sharma S, Vachaspati P, Kumar KN, Giridhar J, Reddy J, Panduga V, Ganguly S, Ahuja V, Gaonkar S, Kumar CN, Ogg D, Tucker JA, Boriack-Sjodin PA, de Sousa SM, Sambandamurthy VK, Ghorpade SR.

J Med Chem. 2013 Nov 14;56(21):8834-48. doi: 10.1021/jm401268f. Epub 2013 Oct 18.

PMID:
24088190
9.

Novel acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor with reduced acyl glucuronide liability: the discovery of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid (AZD8329).

Scott JS, deSchoolmeester J, Kilgour E, Mayers RM, Packer MJ, Hargreaves D, Gerhardt S, Ogg DJ, Rees A, Selmi N, Stocker A, Swales JG, Whittamore PR.

J Med Chem. 2012 Nov 26;55(22):10136-47. doi: 10.1021/jm301252n. Epub 2012 Nov 7.

PMID:
23088558
10.

Discovery of a potent, selective, and orally bioavailable acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor: discovery of 2-[(3S)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-3-piperidyl]acetic acid (AZD4017).

Scott JS, Bowker SS, Deschoolmeester J, Gerhardt S, Hargreaves D, Kilgour E, Lloyd A, Mayers RM, McCoull W, Newcombe NJ, Ogg D, Packer MJ, Rees A, Revill J, Schofield P, Selmi N, Swales JG, Whittamore PR.

J Med Chem. 2012 Jun 28;55(12):5951-64. doi: 10.1021/jm300592r. Epub 2012 Jun 19.

PMID:
22691057
11.

Protein-ligand crystal structures can guide the design of selective inhibitors of the FGFR tyrosine kinase.

Norman RA, Schott AK, Andrews DM, Breed J, Foote KM, Garner AP, Ogg D, Orme JP, Pink JH, Roberts K, Rudge DA, Thomas AP, Leach AG.

J Med Chem. 2012 Jun 14;55(11):5003-12. doi: 10.1021/jm3004043. Epub 2012 May 21.

PMID:
22612866
12.

The structure of the PP2A regulatory subunit B56 gamma: the remaining piece of the PP2A jigsaw puzzle.

Magnusdottir A, Stenmark P, Flodin S, Nyman T, Kotenyova T, Gräslund S, Ogg D, Nordlund P.

Proteins. 2009 Jan;74(1):212-21. doi: 10.1002/prot.22150.

PMID:
18618707
13.

The structure of human collapsin response mediator protein 2, a regulator of axonal growth.

Stenmark P, Ogg D, Flodin S, Flores A, Kotenyova T, Nyman T, Nordlund P, Kursula P.

J Neurochem. 2007 May;101(4):906-17. Epub 2007 Jan 22.

14.

Structures of the hydrolase domain of human 10-formyltetrahydrofolate dehydrogenase and its complex with a substrate analogue.

Kursula P, Schüler H, Flodin S, Nilsson-Ehle P, Ogg DJ, Savitsky P, Nordlund P, Stenmark P.

Acta Crystallogr D Biol Crystallogr. 2006 Nov;62(Pt 11):1294-9. Epub 2006 Oct 18.

PMID:
17057331
15.

Crystallization of a truncated soluble human semicarbazide-sensitive amine oxidase.

Jakobsson E, Nilsson J, Källström U, Ogg D, Kleywegt GJ.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2005 Mar 1;61(Pt 3):274-8. Epub 2005 Feb 8.

16.

Structure of human semicarbazide-sensitive amine oxidase/vascular adhesion protein-1.

Jakobsson E, Nilsson J, Ogg D, Kleywegt GJ.

Acta Crystallogr D Biol Crystallogr. 2005 Nov;61(Pt 11):1550-62. Epub 2005 Oct 19.

PMID:
16239734
17.

The crystal structure of guinea pig 11beta-hydroxysteroid dehydrogenase type 1 provides a model for enzyme-lipid bilayer interactions.

Ogg D, Elleby B, Norström C, Stefansson K, Abrahmsén L, Oppermann U, Svensson S.

J Biol Chem. 2005 Feb 4;280(5):3789-94. Epub 2004 Nov 12.

18.

Crystal structure of the heterodimeric complex of LXRalpha and RXRbeta ligand-binding domains in a fully agonistic conformation.

Svensson S, Ostberg T, Jacobsson M, Norström C, Stefansson K, Hallén D, Johansson IC, Zachrisson K, Ogg D, Jendeberg L.

EMBO J. 2003 Sep 15;22(18):4625-33.

20.

Synthesis and biological activity of a novel class of small molecular weight peptidomimetic competitive inhibitors of protein tyrosine phosphatase 1B.

Larsen SD, Barf T, Liljebris C, May PD, Ogg D, O'Sullivan TJ, Palazuk BJ, Schostarez HJ, Stevens FC, Bleasdale JE.

J Med Chem. 2002 Jan 31;45(3):598-622.

PMID:
11806712
21.

Small molecule peptidomimetics containing a novel phosphotyrosine bioisostere inhibit protein tyrosine phosphatase 1B and augment insulin action.

Bleasdale JE, Ogg D, Palazuk BJ, Jacob CS, Swanson ML, Wang XY, Thompson DP, Conradi RA, Mathews WR, Laborde AL, Stuchly CW, Heijbel A, Bergdahl K, Bannow CA, Smith CW, Svensson C, Liljebris C, Schostarez HJ, May PD, Stevens FC, Larsen SD.

Biochemistry. 2001 May 15;40(19):5642-54.

PMID:
11341829
22.

Crystallization and preliminary X-ray diffraction studies of a new crystal form of human secretory type IIA phospholipase A2.

Church WB, Lei PW, Ogg DJ, Scott KF.

Acta Crystallogr D Biol Crystallogr. 2000 Nov;56(Pt 11):1482-4.

PMID:
11053860
23.

Periplasmic chaperone recognition motif of subunits mediates quaternary interactions in the pilus.

Soto GE, Dodson KW, Ogg D, Liu C, Heuser J, Knight S, Kihlberg J, Jones CH, Hultgren SJ.

EMBO J. 1998 Nov 2;17(21):6155-67.

24.

Structural basis of pilus subunit recognition by the PapD chaperone.

Kuehn MJ, Ogg DJ, Kihlberg J, Slonim LN, Flemmer K, Bergfors T, Hultgren SJ.

Science. 1993 Nov 19;262(5137):1234-41.

PMID:
7901913
25.

Successful outcome after Nd : YAG laser separation of chorioangiopagus-twins under sonoendoscopic control.

Ville Y, Hecher K, Ogg D, Warren R, Nicolaides K.

Ultrasound Obstet Gynecol. 1992 Nov 1;2(6):429-31.

26.

The structure of mouse L1210 dihydrofolate reductase-drug complexes and the construction of a model of human enzyme.

Stammers DK, Champness JN, Beddell CR, Dann JG, Eliopoulos E, Geddes AJ, Ogg D, North AC.

FEBS Lett. 1987 Jun 22;218(1):178-84.

27.
28.

Diagnostic and therapeutic uses of filters in orthoptics and pleoptics.

Cowan LJ, Bennett MM, Ogg DK.

Am Orthopt J. 1966;16:24-9. No abstract available.

PMID:
5936915

Supplemental Content

Support Center